Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: Results 29 to 32 months after third dose

Journal of Infectious Diseases

Volumn 208, Issue 8, 2013, Pages 1325-1334

  Lamontagne, D Scott ^a,b   Thiem, Vu Dinh ^c   Huong, Vu Minh ^a,b   Tang, Yuxiao ^a,b   Neuzil, Kathleen M ^a,b  

^a PATH   (United States)

^b National Institute of Hygiene and Epidemiology ^*

^c National Institute of Hygiene and Epidemiology   (Viet Nam)

Author keywords

adolescents; HPV vaccine; human papillomavirus; immunogenicity; vaccination schedule; Vietnam

Indexed keywords

VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CROSS-SECTIONAL STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNOGENICITY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHOOL CHILD; URBAN RURAL DIFFERENCE; VIET NAM;

ADOLESCENTS; HPV VACCINE; HUMAN PAPILLOMAVIRUS; IMMUNOGENICITY; VACCINATION SCHEDULE; VIETNAM;

ADOLESCENT; ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIETNAM;

EID: 84885038591     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit363     Document Type: Article

References (38)

1. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8.
2. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006; 367:1247-55.
3. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 viruslike particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459-66.
4. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
5. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-51.
6. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14.
7. Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8:309-7.
8. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-45.
9. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents - A randomized controlled trial. Pediatr Infect Dis J 2007; 26:201-9.
10. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40:564-71.
11. Petaja T, Pedersen C, Poder A, et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 2011; 129:2147-57.
12. GlaxoSmithKline Vaccine HPV-007 Study GroupRomanowski B, de Borba PC, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-85.
13. Giuliano AR, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine 2. J Infect Dis 2007; 196:1153-62.
14. Brown DR, Garland SM, Ferris DG, et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 2011; 7:230-8.
15. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-51.
16. Neuzil KM, Canh dG, Thiem VD, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: A cluster randomized noninferiority trial. JAMA 2011; 305:1424-31.
17. Dobson S, Dawar M, Kollman T, et al. A two dose HPV vaccine schedule in girls: Immunogenicity at 24 months. In: Presented at: The 26th International Papillomavirus Conference. Montreal, Quebec, Canada, 2010:609.
18. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2- dose schedule compared to the licensed 3-dose schedule: Results from a randomized study. Hum Vaccin 2011; 7:1374-86.
19. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 Supplement 5:F123-38.
20. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24:5571-83.
21. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25:4931-9.
22. Ferris D. A long-term extension study of Gardasil in adolescents. Presented at The 27th International Papillomavirus Conference. Berlin, Germany, 2011:O-18.05.
23. Dobson SRM, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of human papillomavirus vaccine in younger adolescents versus 3 doses in young women. JAMA 2013; 309:1793-802.
24. Wheeler CM, Bautistia OM, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008; 26:686-96.
25. Krajden M, Cook D, Yu A, et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol 2011; 18:418-23.
26. Smolen KK, Gelinas L, Franzen L, et al. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012; 30:3572-9.
27. Vogel F. Immunologic adjuvants. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines. Philadelphia: WB Saunders, 2004.
28. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11(4 Suppl): S63-S68.
29. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109(2 Suppl):S15-S21.
30. Schwarz TF, Huang LM, Medina DMR, et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health 2012; 50:187-94.
31. Munoz N. Progress in HPV vaccine introduction in Latin America HPV Today 2012; 27:10-11.
32. B.C. Routine Immunization Schedule School Age (14 December 2012). British Columbia Centre for Disease Control [cited 2013 Jan 7]; URL: Http://www.bccdc.ca/NR/rdonlyres/3468D142-C8B6-401B-BF89-63F1C8301871/0/ IMMZschedulewebsiteschoolage-Dec14-2012.pdf Accessed April 26, 2013.
33. Ferreccio C. Satellite Symposium 12: Recommendation for the introduction of the universal HPV vaccination in Chile. 2012. Dec 4; San Juan, Puerto Rico 2012.
34. LaMontagne DS, Barge S, Le NT, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middleincome countries. BullWorld Health Organ 2011; 89:821-830B.
35. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health 2012; 12:370.
36. Quentin W, Terris-Prestholt F, Changalucha J, et al. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. BMC Med 2012; 10:137.
37. Levin CE, Minh HV, Odaga J, et al. Incremental costs of strategies to deliver human papillomavirus vaccine to young adolescent girls in Peru, Uganda, and Viet Nam. BullWorld Health Organ 2013, 91:585-92.
38. Vaccination in the Americas Week, 20-27 April 2013. Pan American Health Organization, 2013 [cited 2013 Jan 2]; URL: Http://new.paho. org/vwa. Accessed April 26, 2013.